drugset / Trial / NCT00476216
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
There is a direct association between cancer and thrombosis (blood clots). The purpose of this study is to determine the best dose of an antithrombotic (prevents blood clots) agent called fondaparinux in non-small cell lung cancer(NSCLC). Patients will also receive chemotherapy.
Timeline
- Start
- 2007-09
- Primary completion
- 2012-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fondaparinux | Other / unclassified | 2.5 mg | Subcutaneous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |